Sun Pharmaceutical Industries Yönetim
Yönetim kriter kontrolleri 4/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Dilip Shanghvi
İcra Kurulu Başkanı
₹60.5m
Toplam tazminat
| CEO maaş yüzdesi | 75.6% |
| CEO görev süresi | 31.7yrs |
| CEO sahipliği | 9.6% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 3.5yrs |
Son yönetim güncellemeleri
Recent updates
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31
We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹111b |
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Tazminat ve Piyasa: Dilip 'nin toplam tazminatı ($USD 720.15K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.11M ).
Tazminat ve Kazançlar: Dilip 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Dilip Shanghvi (69 yo)
31.7yrs
Görev süresi
₹60,541,920
Tazminat
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 426.0b | |
| Executive VP | no data | ₹68.75m | 0.12% ₹ 5.3b | |
| Chief Financial Officer | 7.4yrs | ₹38.89m | Veri yok | |
| Executive Vice-President of Global Operations | no data | Veri yok | Veri yok | |
| EVP & Chief Information Officer | less than a year | Veri yok | Veri yok | |
| VP, Head of Investor Relations & Strategic Projects | no data | Veri yok | Veri yok | |
| Company Secretary & Compliance Officer | 2.8yrs | Veri yok | Veri yok | |
| Director of Corporate Development | no data | ₹65.30m | Veri yok | |
| Chief Human Resources Officer | less than a year | Veri yok | Veri yok | |
| Head of India Business | no data | Veri yok | Veri yok | |
| Chief Executive Officer of North America Business | 8.3yrs | Veri yok | Veri yok | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim: SUNPHARMA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.7yrs | ₹60.54m | 9.6% ₹ 426.0b | |
| Executive VP | 1.4yrs | ₹68.75m | 0.12% ₹ 5.3b | |
| Non-Executive & Non-Independent Director | 30.8yrs | ₹2.20m | 1.8% ₹ 79.8b | |
| Non-Executive & Independent Director | 3.5yrs | ₹5.10m | Veri yok | |
| Non-Executive Independent Director | 6.5yrs | ₹7.80m | Veri yok | |
| Independent Director | 1.4yrs | ₹3.20m | Veri yok | |
| Lead Independent Director | 3.5yrs | ₹8.50m | Veri yok | |
| Independent Director | 2yrs | ₹4.80m | Veri yok |
3.5yrs
Ortalama Görev Süresi
67.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SUNPHARMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).